The overall goal of the Cancer Pharmacokinetics and Pharmacodynamics Core (CPPC) is to provide a high quality resource and state-of-the-art services for measuring pharmacokinetic drug levels of novel and standard chemotherapeutic agents in preclinical animal studies and in clinical studies, and to quantify pharmacodynamic endpoints in preclinical studies as well as for early phase clinical trials. Drug quantitation is achieved through liquid chromatography-tandem mass spectrometry workflows using biological fluids (e.g., blood, serum, urine) and other tissues, including tumors. These measurements can be taken further downstream to produce useful pharmacokinetic data.
Molecular endpoints are obtained through select core immunoassay services using whole cells, cell/tumor extracts or biological fluids. High-throughput, cell-based drug screening assays with multidrug synergy analysis can be used in a preclinical setting or as part of clinical correlative studies. Additional services supporting pre-clinical experimentation include cell-line drug quantitation and pharmacokinetic analysis. Major technical services offered by CPPC are Drug Quantitation, Pharmacokinetic Analysis, Drug Response Assays and Pharmacodynamic Analytical Services.
The CPPC offers a full line of services within these major categories and the ability to work with investigators through collaborative design, to develop and implement both translational science and clinical science experiments in the core under the umbrella of services. In addition, a major function of the CPPC is dedicated to consultation services to Members ranging from experimental design to interpretation of data. The core consists of five full-time highly trained staff members. These kinetic and dynamic services provide cancer center members with invaluable resources to conduct research and play a significant role in establishing the cancer center as a leader in clinical and translational research.
CPPC services include specialized sample processing for research specimens collected in clinical trials and a variety of pharmacologic, whole cell-based and molecular assays:
Drug Quantitation (free and total)
Metabolic Stability/Inhibition Studies
Basic Science (cell lines)
Non-Compartmental & Compartmental Analysis
Molecular Endpoint Analysis
Hematologic Subset Enrichment
ELISA and CBA/Luminex Setup
Drug Screening/Drug Interaction Analysis
384- and 1536-well Plate - Cell Based Assays
Viability/Cytotoxicity/Apoptosis IC50 Analysis
Drug Synergy/Antagonism Analysis (EoHSA/CI)
Please contact the Core by phone or email for more details on current services and pricing.
Andrii Monastyrskyi, PhD
Nelli Bejanyan, MD
Manager, Translational Sciences Shared Resources:
Anthony Neuger, MS
Staff Scientist - Samer Sansil, MS
Staff Scientist - Chris Cubitt, PhD
Research Specialist - Shumin Zhang, MD
Research Specialist - Ashley Blanchard, BS
The Cancer Pharmacokinetics and Pharmacodynamics Core is located in the Moffitt Research Center (MRC) on the first floor, rooms 1304 & 1305.
The Cancer Pharmacokinetics and Pharmacodynamics Core uses a Laboratory Information Management Suite (LIMS) located on the Moffittnet for billing and usage tracking.
All publications based on work conducted in the Cancer Pharmacokinetics and Pharmacodynamics Core should acknowledge the facility. A suggested statement is as follows:
This work has been supported in part by the Cancer Pharmacokinetics and Pharmacodynamics Core at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292)
If a Core Staff member(s) significantly contributes or participates in a project, investigators are encouraged to consider including the individual(s) in the list of authors.